[Clinical analysis of 20 patients with primary non-Hodgkin's lymphoma of nasal cavity and nasopharynx].
To evaluate the treatment policy for non-Hodgkin's lymphoma of the nasal cavity and nasopharynx. Twenty patients with pathologically confirmed non-Hodgkin's lymphoma of nasal cavity and nasopharynx,treated from Jan. 2006 to Oct. 2010, were retrospectively reviewed. The 3-year overall survival and complete response rates for all patients were 78% and 47% respectively. The 3-year overall survival rates for patients treated with chemotherapy and patients treated with chemotherapy plus radiotherapy were 75% and 82% respectively. The estimates of complete response for patients receiving chemotherapy alone and for patients receiving chemotherapy plus radiotherapy were 37% and 55%, respectively. The 3-year overall survival rates for patients who achieved complete response and patients who did not were 89% and 70%, respectively. The 3-year overall survival rates for patients in stage IE and stage II E were 92% and 57%, respectively. There was no significant difference between chemotherapy alone and chemotherapy plus radiotherapy for the treatment of non-Hodgkin's lymphoma of the nasal cavity and nasopharynx. The 3-year overall survival rate for patients in stage IE was much higher than in stage II E. Early treatment is very important to improve the survival rate of the patients.